Clonidine

General characteristics. Structure:

Active ingredient: 1,25 mg, 2,5 mg or 4 mg of a clonidine of a hydrochloride (clonidine) in 1 ml of solution.

Excipients: sodium dihydrophosphate a dihydrate, sodium hydrophosphate dodecahydrate, sodium chloride, water for injections.

Pharmacological properties:

Pharmacodynamics. At a clonidine solution instillation in a conjunctival sac decrease in intraocular pressure happens owing to local adrenomimetichesky action, and also weakening of the sympathetic tone caused by the central effect of a resorptive part of drug.

Decrease in intraocular pressure is caused by reduction of products of intraocular liquid and somewhat improvement of its outflow.

Pharmacokinetics. Drug of local action, a pharmacodynamics it is not studied.

Indications to use:

Primary open angle glaucoma (as monotherapy or in combination with other medicines reducing intraocular pressure).

Route of administration and doses:

Dig in in a conjunctival sac 1-2 drops 2-4 times a day. Treatment begin 0,25% of solution with appointment. In case of insufficient decrease in intraocular pressure use 0,5% solution.

At development of the by-effects connected with use of 0,25% of solution appoint 0,125% solution.

Features of use:

Pregnancy and lactation. Results of clinical trials of clonidine at pregnant women are limited. Use during pregnancy is contraindicated. The clonidine gets into breast milk. therefore in need of use of drug in the period of a lactation it is necessary to stop breastfeeding.

In the absence of effect during the first 1-2 days drug is cancelled. At prolonged use of solution of clonidine it is necessary to control intraocular pressure regularly. At its increase it is necessary to change the medicamentous hypotensive mode.

For reduction of systemic action of drug after instillation it is necessary to press for 1-2 min. a finger area of a dacryocyst.

Influence on ability to manage vehicles and mechanisms. During treatment owing to sedative action it is necessary to be careful during the driving of motor transport and occupation other potentially dangerous types of activity demanding the increased concentration of attention and speed of psychomotor reactions.

Side effects:

Local reactions: dryness of a conjunctiva, an itch or burning in eyes.

System reactions: dryness in a mouth, drowsiness, weakness, locks, a lowering of arterial pressure, bradycardia. Usually these effects gradually weaken and in several days can pass.

Interaction with other medicines:

It is not necessary to appoint together with antidepressants and high doses of antipsychotic medicines (neuroleptics).

Contraindications:

Hypersensitivity, the expressed atherosclerosis of vessels of a brain, arterial hypotension, depressions, pregnancy, lactation, children's age up to 18 years.

With care. Recently postponed myocardial infarction, a chronic renal failure.

Overdose:

Increases expressiveness of side effects. Drug is cancelled. Symptomatic treatment.

Storage conditions:

List No. 1 of strong substances PKKN. In protected from light and the place, unavailable to children, at a temperature not above 15 degrees Celsius. A period of validity - 2 years. Not to use after the period of validity specified on packaging.

Issue conditions:

According to the recipe

Packaging:

Drops eye 0,125%, 0,25% and 0,5%. In a tube droppers from polyethylene on 1,3 ml. On the 5th tube droppers with the application instruction of drug and the application instruction a tube dropper in a pack from a cardboard with partitions from a film polyvinyl chloride either from polyethylene, or from a cardboard, or without partitions.